虚假陈述
Search documents
部分世纪华通投资者索赔获赔到位
Xin Lang Cai Jing· 2025-09-24 07:41
Core Viewpoint - The article discusses the legal developments regarding Century Huatong (002602) related to investor claims due to false statements, highlighting ongoing litigation and the company's violations as determined by regulatory authorities [1][2]. Group 1: Legal Developments - In September 2025, significant progress was made in investor claims against Century Huatong, with some investors already compensated and the case concluded [1]. - On September 21, 2025, additional claims were filed against Century Huatong in Shaoxing Intermediate People's Court, with the legal team continuing to accept claims from other investors [1]. Group 2: Regulatory Findings - On November 6, 2024, Century Huatong received an administrative penalty decision from the China Securities Regulatory Commission, confirming the following violations: - False records regarding goodwill in annual reports from 2018 to 2022 [1]. - Fabrication of software copyright transfer transactions and premature revenue recognition, leading to false records in annual reports for 2020 and 2021 [1]. - Specific instances include the fictitious software copyright transfer of "Millennium 3" in 2020, which inflated revenue, and premature recognition of revenue from "Rainbow Alliance" software copyright transfer, affecting both 2020 and 2021 financials [1].
C3.ai, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before October 21, 2025 to Discuss Your Rights – AI
Globenewswire· 2025-09-18 20:37
Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance [3][4]. Company Summary - The class period for the lawsuit is from February 26, 2025, to August 8, 2025 [3]. - Allegations include that C3 AI's management provided overly positive statements while concealing material adverse facts about the company's growth potential and the CEO's health issues [3]. - On August 8, 2025, C3 AI announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing this to "the reorganization with new leadership" and the CEO's health [3]. - Following this announcement, C3 AI's stock price dropped from $22.13 per share to $16.47 per share, a decline of approximately 25.58% in just one day [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by October 21, 2025 [4]. - Registration allows shareholders to receive updates on the case and does not involve any cost or obligation [4]. Legal Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].
鼎信通讯股民索赔获得终审胜诉,思创医惠索赔案持续推进
Xin Lang Cai Jing· 2025-09-17 09:13
Core Viewpoint - The article discusses significant legal developments regarding investor compensation lawsuits against Dingxin Communications (603421) and Sichuang Medical (300078) due to false statements and financial misconduct [1][2]. Group 1: Dingxin Communications (603421) - Dingxin Communications has been ordered by the Shandong High Court to pay a total of 32,800.75 yuan in a lawsuit related to false statements, following a previous ruling by the Qingdao Intermediate People's Court [1]. - The company failed to timely disclose significant changes in external conditions affecting its operations, specifically regarding the State Grid's procurement freeze, which had a major impact on its revenue [1]. - The company also did not disclose the disposal of shares by its controlling shareholder and actual controller, which is another basis for potential investor claims [2]. Group 2: Sichuang Medical (300078) - The investor compensation case against Sichuang Medical is ongoing, with a lawsuit filed in Wenzhou Intermediate Court, following previous successful claims by investors [2]. - The company has been found to have fabricated significant false information in its public offering documents and had false records in its annual reports for 2019 and 2020 [3][4]. - Investors who purchased Sichuang Medical shares between April 30, 2020, and October 29, 2022, may still initiate claims, as the case is approaching the statute of limitations [5].
获赔26万!2个小股民赢了!普华永道承担3%连带赔偿责任
券商中国· 2025-05-10 07:48
Core Viewpoint - The article discusses the recent legal developments involving Huichen Co., which has been found liable for false statements during its IPO and subsequent annual reports, leading to a court ruling for partial compensation to investors [1][2]. Summary by Sections Legal Proceedings - Huichen Co. has been sued by three small investors for compensation of approximately RMB 377,252.59 due to alleged false statements [2]. - The Shanghai Financial Court ruled that Huichen Co. must compensate two investors a total of RMB 260,880.15, with PwC bearing 3% of the liability [1][2]. Financial Penalties - The company has been penalized with a fine of RMB 5 million for violations related to false disclosures in its IPO documents and annual reports from 2020 to 2022 [3]. Audit Issues - PwC received a warning letter from the Beijing Securities Regulatory Bureau for inadequate auditing practices during Huichen Co.'s IPO and subsequent financial statements [5][7]. - Specific issues included insufficient audit procedures regarding revenue and accounts receivable, leading to a lack of detection of irregularities [6]. Company Response - Huichen Co. stated it would assess the court's ruling and decide on an appeal within the legal timeframe, while also ensuring that the lawsuit does not affect its normal business operations [2].